Sutro Biopharma STRO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's total current liabilities?
- Sutro Biopharma (STRO) reported total current liabilities of $70.81M in Q1 2026.
- How has Sutro Biopharma's total current liabilities changed year-over-year?
- Sutro Biopharma's total current liabilities decreased by 46.8% year-over-year, from $133.05M to $70.81M.
- What is the long-term trend for Sutro Biopharma's total current liabilities?
- Over 5 years (2020 to 2025), Sutro Biopharma's total current liabilities has grown at a 20.5% compound annual growth rate (CAGR), from $29.6M to $75.13M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.